Butylone

Butylone's sympathomimetic effects produce tachycardia and hypertension via norepinephrine and dopamine reuptake inhibition. Individuals with long QT syndrome face elevated risk of torsades de pointes and sudden cardiac death.

Individuals with cardiomyopathy, valvular disease, or coronary artery disease face elevated risk from butylone's sympathomimetic cardiovascular effects. The Warrick case documented heart rate of 158 bpm during acute toxicity.

Class-level evidence that sympathomimetic stimulants lower seizure threshold. Butylone's combined monoaminergic activity may increase seizure risk in individuals with epilepsy or other seizure-prone conditions.

DAT-active stimulants reliably worsen positive symptoms of psychosis. Butylone's DAT blocking activity combined with serotonergic effects creates risk of acute psychotic decompensation in vulnerable individuals.

Combined dopaminergic and serotonergic stimulation can precipitate mania. Risk is elevated during depressive phases when patients may self-medicate with stimulants.

Butylone undergoes CYP450-mediated bioactivation producing hepatotoxic metabolites. Individuals with pre-existing liver disease face uncertain but potentially elevated hepatotoxicity risk. The direction of risk (more or less toxic metabolite generation) depends on which CYP isoforms are affected.

No reproductive toxicity studies have been conducted. Sympathomimetic effects risk placental vasoconstriction and fetal distress. Serotonergic activity during critical neurodevelopmental periods poses theoretical teratogenic risk.

The Warrick (2012) case documents fatal serotonin syndrome from combined serotonergic cathinone ingestion. Any concurrent serotonergic medication (MAOIs, SSRIs, SNRIs, tramadol, triptans, lithium) is absolutely contraindicated.